Summary & Overview
HCPCS J2251: Midazolam Injection, IV, 1 mg
HCPCS Level II code J2251 identifies a 1 mg unit of midazolam in 0.9% sodium chloride for intravenous use, specified as not therapeutically equivalent to J2250. The code matters nationally because midazolam is a commonly used benzodiazepine for procedural sedation, anesthesia adjuncts, and short-term sedation in a range of care settings; accurate coding affects claims processing, inventory tracking, and clinical documentation. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare.
Readers will find a concise briefing on what the code represents, the clinical contexts in which it is used, typical sites of service, and how the code fits into billing workflows. The report summarizes benchmark considerations, common modifiers used with HCPCS drug codes, and policy-relevant points such as payer coverage patterns and documentation expectations. Where specific payer policies or reimbursement benchmarks are available, those are summarized; where not available, the text notes that data is not provided. The intent is to give clinical, coding, and billing teams a clear reference for applying J2251 in national practice settings.
Billing Code Overview
HCPCS Level II code J2251 represents an intravenous injection of midazolam diluted in 0.9% sodium chloride, specified as not therapeutically equivalent to J2250, with a unit of 1 mg. This code denotes the drug preparation and route of administration rather than procedure or facility charges.
Service Type: Intravenous sedative/anxiolytic medication administration
Typical Site of Service: Hospital inpatient or outpatient departments, ambulatory surgery centers, and other clinical infusion settings where intravenous sedation is provided
Clinical & Coding Specifications
Clinical Context
A 55-year-old male scheduled for outpatient endoscopic retrograde cholangiopancreatography (ERCP) for suspected choledocholithiasis receives intra-procedural intravenous sedation. The clinician administers J2251 (midazolam in 0.9% sodium chloride, intravenous, 1 mg) as an incremental bolus to achieve moderate sedation in combination with analgesic agents. The medication is prepared and documented by nursing under the physician’s order, including dosage, lot number, route, and time. Sedation level, respiratory status, blood pressure, and oxygen saturation are monitored continuously before, during, and after the procedure. Post-procedure, the patient is observed in the recovery area until discharge criteria are met or advanced care is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | Use when part of the prepared vial or dose is wasted and must be reported to document discarded medication. |
JZ | No drug product wastage | Use when the exact amount prepared is administered and no wastage occurred. |